ArticleFrontiers in medicine2026

Individualized duration of adjuvant alectinib therapy and rechallenge efficacy in ALK-positive non-small cell lung cancer: a case report.

Junliang Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.